Vol 5, Supplement 3 (September 2016): Translational Cancer Research

Editorial

Tailor the adjuvant hormonal manipulation for premenopausal breast cancer patients
Tom Wei-Wu Chen, Ching-Hung Lin, Yen-Shen Lu
Adjuvant chemotherapy for locally advanced bladder cancer—a step closer to ending the ongoing controversy
Sanjay Patel, Michael Cookson
More is not always better: clinical genetics of familial breast cancer in the era of massively enhanced sequencing capacities
Martin Schreiber
Akt1/Akt2 inhibition and development of hepatocellular carcinoma
Rosina Maria Critelli, Filippo Schepis, Erica Villa
Mutational and transcriptome based sub-classification of pancreatic cancer: are we there yet?
Vrishketan Sethi, Bharti Garg, Ashok Saluja, Vikas Dudeja
A lovely leap toward the development of breast cancer therapy with long non-coding RNAs
Tomoshige Kino, Alexandra K. Marr
Multimodality imaging for early assessment of head and neck patients during induction chemotherapy: a reliable future option?
Filippo Alongi, Rosario Mazzola
Immune checkpoint blockade (ICB) for first line treatment in non-small-cell lung cancer (NSCLC)
Rafael Rosell, Niki Karachaliou, Aaron Sosa, Santiago Viteri
Post radiofrequency ablation assessment of colorectal cancer liver metastases—does post ablation biopsy really matter?
Hanping Wu, Agata A. Exner, Sidhartha Tavri
The CROSS road in neoadjuvant therapy for esophageal cancer: long-term results of CROSS trial
Ian Wong, Simon Law
Personalized molecular targeted therapy for hepatocellular carcinoma in the era of genome sequencing
Massimiliano Cadamuro, Mario Strazzabosco, Luca Fabris
Afatinib and gefitinib: a direct comparison
Cesare Gridelli, Tania Losanno
Another important step towards understanding tumor immune evasion—novel mechanisms of PD-L1 overexpression
Young Kwang Chae, Ayush Arya, Jonathan Anker, Francis Giles
Balancing redox stress: anchorage-independent growth requires reductive carboxylation
Clint.A Stalnecker, Ahmad.A Cluntun, Richard.A Cerione
Chemo-radiotherapy free conditioning regimen: immunotoxin at its magical best
Ranjit Kumar Sahoo, Lalit Kumar
Novel toxicology challenges in the era of chimeric antigen receptor T-cells therapies
Kentaro Minagawa, Antonio Di Stasi
Should we incorporate ablative radiotherapy in standard treatment of advanced intrahepatic cholangiocarcinoma?
Giovanni Brandi, Andrea Palloni, Alessio Giuseppe Morganti
Durvalumab (MEDI4736; anti-PD-L1 inhibitor): to shed light on the treatment of advanced urothelial bladder cancer patients refractory to systemic chemotherapy
Minyong Kang, Ja Hyeon Ku
Expanding therapies for crizotinib refractory ALK-rearranged nonsmall cell lung cancer
Tristan A. Barnes, Natasha B. Leighl
Adjuvant therapy for resected early-stage small-cell lung cancer: is now time to rethink about that?
Roberto Ferrara, Mario Caccese, Federica Cuppone, Emilio Bria, Giampaolo Tortora, Sara Pilotto
BIRC3 as a yet underestimated prognostic marker of malignancies?
Thomas Liehr
Atezolizumab in lung cancer—appreciating the differences
Stephen V. Liu, Giuseppe Giaccone
Pushing the limits in pancreatic cancer therapy
Dionysios Koliogiannis, Jens Werner, Werner Hartwig

Commentary

Directing abiraterone metabolism: balancing the scales between clinical relevance and experimental observation
Jon K. Obst, Marianne D. Sadar
Immune checkpoint inhibitors in non-small cell lung cancer: is simultaneous blockade better?
Jennifer T. Eubanks, Suresh S. Ramalingam
Colonic crypts are natural gatekeepers of microbial metabolites to protect stem cells
Praveen Kumar Vemula, Venkatakrishna Rao Jala
Theranostic siRNA conjugated nanoparticles: the possible central role of superparagmetic iron oxide nanoparticles as a new transfer vehicle system for therapy and diagnostic in human cancer therapy
Eckhard Klieser, Daniel Neureiter
Mastectomy in precision oncology era: myth or reality?
Gianluca Franceschini, Armando Orlandi, Alejandro Martin Sanchez, Maria Alessandra Calegari, Riccardo Masetti
Some aspects of mutant p53 in ovarian cancer biology
Sabine Heublein
Commentary on a randomized controlled trial of vagus nerve- preserving distal gastrectomy in early gastric cancer
Mikita Inokuchi, Sho Otsuki, Tatsuyuki Kawano, Kazuyuki Kojima
Drivers of neuroendocrine prostate cancer
Filipe Pinto, Rui Manuel Reis
Crizotinib for ALK rearrangement-positive non-small cell lung cancer patients with central nervous system metastasis
Masayuki Takeda, Kazuhiko Nakagawa
Helicobacter pylori vacuolating cytotoxin and gastric cancer risk: reconsidered
Muhammad Miftahussurur, Yoshio Yamaoka, David Y. Graham
Extracellular vesicles in cancer: current status and challenges
Nami O. Yamada
Long non-coding RNAs: new opportunities and old challenges in cancer therapy
Gwyn T. Williams, Mark R. Pickard
GAS5 oligonucleotides as therapeutic agents in breast cancer
Merdan Fayda, Ugur Gezer
Estrogen receptor and human epidermal growth factor receptor-2 quantification and efficacy to trastuzumab
Paolo Nuciforo
ETV1 combines tumor cell plasticity with constitution of a pro-tumorigenic stroma in pancreatic cancer
Robert Götze, Volker Ellenrieder
Video-assisted thoracoscopic surgery or open thoracotomy approach for surgery for non-small cell lung cancer—no definitive answer, yet
Marcin Zielinski
Predicting the response to anti-PD1 therapy in metastatic melanoma
Lucie Heinzerling, Michael Constantin Kirchberger, Lisa Walter, Gerold Schuler
Oncogenic combined calcineurin-nuclear factor of activated T cells and toll-like receptor signals in colon
Masashi Muramatsu, Takashi Minami
The role of the liquid biopsy as a clinical tool for early prediction in prostate cancer
Michael J. Donovan
Cyclin dependent kinase 5—a novel target to enhance the antitumor immune response
Johanna Liebl
Bendamustine and rituximab for the treatment of relapsed indolent and mantle cell lymphoma: when timing of a study matters
Lorenzo Falchi, Rita Morales, Marco Ruella
Signals derived from the commensal microbiota to promote intestinal tumor development
Swapna Chaudhuri